Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study
Kenneth F Hofland, Steinbjørn Hansen, Morten Sorensen, Silke Engelholm, Henrik P Schultz, Aida Muhic, Kirsten Grunnet, Anders Ask, Junia C Costa, Charlotte Kristiansen, Carsten Thomsen, Hans Skovgaard Poulsen, Ulrik Lassen
Dive into the research topics of 'Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study'. Together they form a unique fingerprint.